-
According to a new economic analysis of the DC Female Condom program, a public-private partnership to provide and promote FC2 Female Condoms (Female Health Co., Chicago), the program prevented enough HIV infections in the first year alone to save more than $8 million in future medical care costs over and above the cost of the program.
-
Get ready to add two sets of guidance on cervical cancer screening to your practice database: the most current recommendations from the U.S. Preventive Services Task Force (USPSTF) and joint cervical cancer prevention guidelines issued by the American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology (ACS/ASCCP/ASCP).
-
How many chlamydia tests were performed on sexually active women ages 15-25 in your clinic last year? If your numbers are similar to a new national analysis, about 38% of sexually active young women ages 15-25 were screened for the sexually transmitted disease (STD).
-
About three million U.S. women experience heavy menstrual bleeding each year.1 With the recent Food and Drug Administration (FDA) approval of Natazia (Bayer HealthCare Pharmaceuticals, Wayne, NJ) for treatment in women who choose an oral contraceptive (OC), clinicians now have another therapeutic option.
-
When routinely cultured, essentially all ICU privacy curtains were found to be contaminated with potential pathogens at least some of the time. Recovered organisms included methicillin-resistant staphylococci and vancomycin-resistant enterococci.
-
In this study population with a 2% average risk of a major coronary event per year, LDL cholesterol, apolipoproteins, and LDL particle concentrations had similar and strong associations for major vascular events. The independent predictive value of HDL measures is less clear.
-
Clinical Briefs: Coffee Might be One Less Thing We Have to Worry About; ED, Lower Urinary Tract Symptoms, and Ejaculatory Dysfunction; The Allure of Shared Medical Appointments in Diabetes Care
-
A BETA-3 ADRENERGIC AGONIST HAS BEEN APPROVED FOR the treatment of overactive bladder in adults. Mirabegron differs from other agents approved for this same indication, such as oxybutynin, tolterodine, solifenacin, darifenacin, etc., which are anticholinergic/antimuscarinic agents. Mirabegron is marketed by Astellas Pharma as Myrbetriq.
-
-
The practice of tanning by artificial means, such as by sunlamps or sunbeds, continues to be popular, particularly in young people despite the acknowledged risk for increased skin cancer.
